New Weight-Loss drug candidate passes early safety check in healthy volunteers
NCT ID NCT05313802
First seen May 27, 2026 · Last updated May 27, 2026
Summary
This early-stage study tested a new drug called LY3502970 in 72 healthy overweight and obese adults. The main goal was to see if the drug is safe and how the body handles it. Participants were monitored for up to 42 days, and blood tests measured drug levels. The study did not aim to treat a disease but to gather safety data for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON Early Phase Services
San Antonio, Texas, 78209, United States
-
ICON Early Phase Services Lenexa Center
Lenexa, Kansas, 66219, United States
-
Qps-Mra, Llc
Miami, Florida, 33143, United States
Conditions
Explore the condition pages connected to this study.